AI-generated conceptual illustration of cross-linking; not a procedural diagram.
A changing glasses prescription can have several explanations. In keratoconus, the cornea, the clear front surface of the eye, becomes thinner and changes shape. Its increasingly irregular curve distorts how light is focused. Corneal cross-linking has changed the management of this condition by offering a way to strengthen the cornea and reduce the risk of further progression. Choosing treatment still requires careful assessment of the individual eye.
Why measurements over time matter
Keratoconus often begins in the teenage years or early adulthood. Symptoms can include increasing astigmatism, blur that glasses do not fully correct, glare, and repeated prescription changes. The condition progresses at different rates, so symptoms alone cannot reliably establish whether it is worsening. Corneal topography and tomography map the cornea's shape; thickness measurements add further information. Comparing scans and vision tests over time helps the ophthalmologist judge progression. Moorfields keratoconus guide
Bring previous prescriptions and scans if available. Tell your clinician about allergies and frequent eye rubbing. Avoid rubbing your eyes, and ask how to manage itching safely. Monitoring intervals should reflect your age, scan findings, and likelihood of progression rather than follow a single timetable for everyone. Royal Devon patient guide, cross-linking assessment
What cross-linking is intended to achieve
Cross-linking combines riboflavin, a form of vitamin B2, with controlled ultraviolet-A light to strengthen the corneal tissue. The main aim is to preserve stability. Some people gain better vision, but treatment does not reliably restore a normal corneal shape or remove the need for glasses or contact lenses. Moorfields cross-linking guide
Glasses, rigid contact lenses, and specialist lens designs address how well a person sees. Cross-linking addresses progression. Advanced scarring or difficulty achieving useful vision may require other treatment, including a corneal transplant in selected cases. National Eye Institute
Epi-off: an established approach
In epithelium-off, or epi-off, treatment, the thin surface layer of the cornea is removed so riboflavin can penetrate. Ultraviolet exposure follows under a defined protocol. In a randomized trial with three-year follow-up, treated eyes showed improved average corneal-curvature measurements, while untreated control eyes continued to worsen. This supports treatment for appropriately selected progressive disease. Wittig-Silva and colleagues, 2014
In the United States, the FDA-approved Photrexa/KXL epi-off regimen has indications for progressive keratoconus and corneal ectasia after refractive surgery, with initial approval in 2016. Its label specifies the treatment method and thickness safeguards, and states that safety and effectiveness below age 14 have not been established. Regulatory approval and current product availability are separate questions. FDA Photrexa label
Epi-on: an important recent change
Epithelium-on, or epi-on, methods retain the surface layer. Different formulations and light-delivery systems should be evaluated separately.
On October 20, 2025, Glaukos announced U.S. FDA approval of Epioxa HD/Epioxa for keratoconus. The FDA label covers adults and children aged 13 years and older, using the specified O2n System and Boost Goggles. This oxygen-enriched treatment has its own clinical-trial evidence. It is inaccurate to describe every epi-on procedure as investigational in the United States. Approval announcement, FDA Epioxa label
The pivotal Epioxa studies compared treatment with a sham procedure, rather than directly with established epi-off treatment. They therefore do not establish that this approach is superior to epi-off. Reported adverse effects included redness, haze, light sensitivity, pain, and reduced visual acuity. These are U.S. regulatory details; approval, availability, and eligibility elsewhere require local verification. FDA clinical-study and safety information
What else is being studied?
Customized cross-linking uses corneal maps to vary the treatment pattern. A study published in 2026 followed 179 eyes for two years and reported greater average corneal flattening with a customized epi-on protocol than with an accelerated epi-off protocol. However, it was a single-center, nonrandomized study, so differences between the patient groups could influence the findings. It adds useful evidence but does not establish the best protocol for every eye. Results from one customized treatment should not be assumed to apply to every epi-on system. Halašová and colleagues, 2026
Recovery, risks, and the next decision
After epi-off treatment, discomfort and light sensitivity are expected while the surface heals. A bandage contact lens and prescribed drops are commonly used. Vision can fluctuate, and follow-up scans remain important because progression can occasionally continue. Haze, delayed healing, infection, scarring, and lasting vision reduction are possible. Severe pain or a sudden drop in vision needs urgent assessment. Moorfields recovery guidance, FDA safety information
Ask which exact protocol is proposed, what evidence supports it for your corneal thickness and stage of disease, and how success will be measured. A shorter treatment or an intact surface alone does not establish the best long-term result. A comprehensive eye examination can help identify the need for a focused corneal assessment and an individualized monitoring plan.
Related reading
This article is for general education and does not replace an examination, diagnosis, or treatment plan from your ophthalmologist. The options described may not be suitable or available for every patient.
Sources
- Moorfields Eye Hospital NHS Foundation Trust. Keratoconus (Accessed 2026-10-05).
- Moorfields Eye Hospital NHS Foundation Trust. Corneal cross linking (Accessed 2026-10-05).
- National Eye Institute. Corneal Dystrophies: Keratoconus (Accessed 2026-10-05).
- Wittig-Silva C, Chan E, Islam FMA, Wu T, Whiting M, Snibson GR. A Randomized, Controlled Trial of Corneal Collagen Cross-Linking in Progressive Keratoconus: Three-Year Results (2014).
- U.S. Food and Drug Administration. PHOTREXA VISCOUS and PHOTREXA: Full Prescribing Information, revised February 2025 (2025).
- Glaukos Corporation. Glaukos Announces FDA Approval of Epioxa (2025-10-20).
- U.S. Food and Drug Administration. EPIOXA HD and EPIOXA: Full Prescribing Information, revised October 2025 (2025).
- Halašová Z, Stodůlka P, Škrovinová L, Rakušanová S, Slovák M, Randárová E. Comparison of epithelium-on customized remodeled vision and epithelium-off accelerated crosslinking in keratoconus treatment: 2-year study (2026).
- Royal Devon University Healthcare NHS Foundation Trust. Keratoconus: Patient Information (Accessed 2026-10-05).
Evidence checked: 5 October 2026.
